Sign in

Colorectal cancer: trials that stopped early

Trials on Colorectal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

254 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.

  1. Terminated

    Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers

    Reason given in the registry

    “Due to a lack of safety and efficacy.”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Jan 2025.

    Ended
    Jul 2024
    Phase
    Phase 1
    Run by
    The Netherlands Cancer Institute
    Registry record
    NCT04916236
  2. Terminated

    Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

    Reason given in the registry

    “Study was terminated due to strategic considerations and not due to safety.”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Jan 2025.

    Ended
    Nov 2023
    Phase
    Phase 1
    Run by
    Pfizer
    Registry record
    NCT04171141
  3. Terminated

    Oral AMXT 1501 Dicaprate in Combination With IV DFMO

    Reason given in the registry

    “Required re-formulation of DFMO from IV to capsule to maintain safety”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Dec 2024.

    Ended
    Dec 2024
    Phase
    Phase 1/2
    Run by
    Aminex Therapeutics, Inc.
    Registry record
    NCT05500508
  4. Terminated

    Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)

    Reason given in the registry

    “The overall profile does not support development for metastatic colorectal cancer”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Dec 2024.

    Ended
    Mar 2024
    Phase
    Phase 1
    Run by
    Taipei Medical University Shuang Ho Hospital
    Registry record
    NCT05281276
  5. Withdrawn

    Improving Outpatient Colonoscopy Bowel Prep With the Orton Score

    Reason given in the registry

    “Not enough funding for research coordinator.”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Dec 2024.

    Ended
    Dec 2024
    Run by
    University of Virginia
    Registry record
    NCT04093557
  6. Withdrawn

    Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases

    Reason given in the registry

    “PI left the institution”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Dec 2024.

    Ended
    Dec 2024
    Phase
    Phase 1
    Run by
    University of Colorado, Denver
    Registry record
    NCT03802747
  7. Terminated

    Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.

    Reason given in the registry

    “Due to development strategy change.”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Dec 2024.

    Ended
    Jun 2024
    Phase
    Phase 1
    Run by
    ABM Therapeutics Corporation
    Registry record
    NCT05831995
  8. Terminated

    Comparison Between Tailored Surgery Versus Total Mesorectal Excision in ycT2-3N0M0

    Reason given in the registry

    “the high proportion of patients requiring TME(control group) suggests that proceeding with a randomized prospective clinical trial may not be feasible.”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Dec 2024.

    Ended
    Aug 2024
    Run by
    Seoul National University Hospital
    Registry record
    NCT05164315
  9. Withdrawn

    Effectiveness of Aquatic Exercise on Fatigue, Neuropathy and Quality of Life Among Cancer Patients

    Reason given in the registry

    “The study was stopped because we were unable to recruit participants as planned. Therefore, it was decided to halt the study and participant recruitment.”

    Quoted unchanged from ClinicalTrials.gov; record updated 26 Nov 2024.

    Ended
    Nov 2024
    Run by
    Tel Aviv University
    Registry record
    NCT05427344
  10. Terminated

    ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

    Reason given in the registry

    “Company decision to wind down operations, close all clinical programs and evaluate strategic options”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Nov 2024.

    Ended
    Jul 2024
    Phase
    Phase 1
    Run by
    MEI Pharma, Inc.
    Registry record
    NCT05824559
  11. Withdrawn

    Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer

    Reason given in the registry

    “Abandoned 9/23/24”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Nov 2024.

    Phase
    Phase 2
    Run by
    City of Hope Medical Center
    Registry record
    NCT06575725
  12. Withdrawn

    Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy

    Reason given in the registry

    “PI decision.”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Nov 2024.

    Ended
    Feb 2025
    Run by
    Indiana University
    Registry record
    NCT04192929
  13. Terminated

    A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination

    Reason given in the registry

    “Strategic business decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Nov 2024.

    Ended
    Aug 2024
    Phase
    Phase 1
    Run by
    Pfizer
    Registry record
    NCT06448364
  14. Terminated

    Exercise Preconditioning with Cancer Surgeries

    Reason given in the registry

    “Company providing the computer application for exercise intervention suddenly closed for business”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2024.

    Ended
    Sept 2024
    Run by
    University of Virginia
    Registry record
    NCT04923672
  15. Terminated

    Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC

    Reason given in the registry

    “Due to poor clinical trial accrual, the study was terminated.”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 Oct 2024.

    Ended
    Dec 2023
    Phase
    Phase 2
    Run by
    Shanghai Henlius Biotech
    Registry record
    NCT05584137
  16. Terminated

    PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin

    Reason given in the registry

    “Business reason”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Oct 2024.

    Ended
    Sept 2024
    Phase
    Phase 1
    Run by
    EXACT Therapeutics AS
    Registry record
    NCT04021277
  17. Withdrawn

    Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)

    Reason given in the registry

    “prioritization of studies”

    Quoted unchanged from ClinicalTrials.gov; record updated 26 Sept 2024.

    Ended
    Oct 2026
    Phase
    Phase 2
    Run by
    Roswell Park Cancer Institute
    Registry record
    NCT05518032
  18. Withdrawn

    Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer

    Reason given in the registry

    “Lack of funding.”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Sept 2024.

    Ended
    Jun 2026
    Phase
    Phase 3
    Run by
    Johannes Laengle, MD, PhD
    Registry record
    NCT04488159
  19. Terminated

    Well-being and Stress Control After Colorectal Surgery

    Reason given in the registry

    “recruitment difficulties”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.

    Ended
    Sept 2024
    Run by
    University Hospital, Strasbourg, France
    Registry record
    NCT03844347
  20. Withdrawn

    Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

    Reason given in the registry

    “no sites were regulatory ready and the SC took the study to a different group.”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.

    Ended
    Sept 2024
    Phase
    Phase 2
    Run by
    Academic and Community Cancer Research United
    Registry record
    NCT05356897
  21. Withdrawn

    Intraperitoneal LSTA1 in CRS-HIPEC

    Reason given in the registry

    “closed early due to low (0) accrual”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Aug 2024.

    Ended
    Jun 2024
    Phase
    Phase 1
    Run by
    University of California, San Diego
    Registry record
    NCT06216561
  22. Terminated

    Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

    Reason given in the registry

    “Business Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Aug 2024.

    Ended
    Jun 2024
    Phase
    Phase 1
    Run by
    Asahi Kasei Therapeutics, Inc.
    Registry record
    NCT05251727
  23. Withdrawn

    Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

    Reason given in the registry

    “withdrawn”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Aug 2024.

    Ended
    Oct 2025
    Phase
    Early phase 1
    Run by
    City of Hope Medical Center
    Registry record
    NCT05672342
  24. Terminated

    A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

    Reason given in the registry

    “The Sponsor terminated the study because development of cibisatamab has been discontinued.”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Aug 2024.

    Ended
    Mar 2024
    Phase
    Phase 1
    Run by
    Hoffmann-La Roche
    Registry record
    NCT03866239
  25. Terminated

    Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

    Reason given in the registry

    “Sponsor decision (not related to safety, efficacy or quality).”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Jul 2024.

    Ended
    Mar 2024
    Phase
    Phase 1
    Run by
    Hoffmann-La Roche
    Registry record
    NCT05769959
  26. Withdrawn

    Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

    Reason given in the registry

    “Due to slow patient recruiting. No patients were enrolled 12 months after study initiation.”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Jul 2024.

    Ended
    Jul 2025
    Phase
    Phase 2
    Run by
    Sun Yat-sen University
    Registry record
    NCT05690035
  27. Withdrawn

    GI Organ Tracking Via Balloon Applicators

    Reason given in the registry

    “Low accrual”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Jun 2024.

    Ended
    May 2025
    Run by
    Washington University School of Medicine
    Registry record
    NCT05471401
  28. Terminated

    Electroporation and Immunotherapy in Metastatic Colorectal Cancer

    Reason given in the registry

    “The study was terminated on the basis on an evaluation of the efficacy and safety of the 4 included and treated patients.”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Jun 2024.

    Ended
    May 2024
    Phase
    Phase 2
    Run by
    Ismail Gögenur
    Registry record
    NCT05609656
  29. Terminated

    Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

    Reason given in the registry

    “Not related to safety concerns or lack of efficacy”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 May 2024.

    Ended
    Apr 2024
    Phase
    Phase 1
    Run by
    ABM Therapeutics Corporation
    Registry record
    NCT04190628
  30. Terminated

    RITUAL Ultivision AI CADe Randomized Controlled Trial

    Reason given in the registry

    “Business decision to discontinue the study. Discontinuation is not related to any patient safety or performance issues.”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 May 2024.

    Ended
    Feb 2024
    Run by
    Satisfai Health, Inc.
    Registry record
    NCT05732233

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.